NCT05930925 is a Phase 1 clinical trial of [phenyl-14C]ARV-471 in Healthy, sponsored by Pfizer.

Who is sponsoring NCT05930925?

NCT05930925 is sponsored by Pfizer.

What drugs are being tested in NCT05930925?

Interventions in NCT05930925: [phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471.

Is NCT05930925 still recruiting?

NCT05930925 is currently completed. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT05930925

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

Completed Phase 1 Last updated 13 September 2023

What this trial tests

Phase 1 trial testing [phenyl-14C]ARV-471 in Healthy in 12 participants. Completed in 14 August 2023.

Timeline

12 June 2023

Primary endpoint
27 July 2023

14 August 2023

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	12
Start date	12 June 2023
Primary completion	27 July 2023
Estimated completion	14 August 2023
Sites	1 location across United States

Drugs / interventions tested

[phenyl-14C]ARV-471 — full drug profile →
[oxoisoindolin-14C]ARV-471 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to understand how the study medicine ARV-471 is processed in the body of healthy males and females who do not have the potential to have children. This study is seeking for participants who: * are healthy males and females who do not have the potential to have children. * are 18 years of age or older. * weigh more than 110 pounds.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

PROTAC Technology as a New Tool for Modern Pharmacotherapy.
Kubryń N, Fijałkowski Ł, Nowaczyk J, Jamil A, et al · · 2025 · cited 13× · PMID 40430296 · DOI 10.3390/molecules30102123
Proteolysis-Targeting Chimera (PROTAC): Current Applications and Future Directions.
Fan G, Chen S, Zhang Q, Yu N, et al · · 2025 · cited 6× · PMID 41049269 · DOI 10.1002/mco2.70401
PROTAC-based protein degradation: a window of opportunity for melanoma therapy.
Gentile G, D'Aguanno S, Di Martile M, Petricca A, et al · · 2026 · PMID 41761284 · DOI 10.1186/s12929-026-01225-2
Recent advances in targeting protein degradation for tumor immunotherapy.
Li S, Jin Y, Wu H, Yuan H, et al · · 2025 · PMID 41345706 · DOI 10.1186/s13045-025-01765-4
Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling.
He Y, Zhu C, Lei P, Yang C, et al · · 2025 · PMID 40496072 · DOI 10.1016/j.jpha.2024.101175

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05930925 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05930925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing